CBLL Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$28.00median target· current $24.50 (+14.3%)8 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.730.0% YoY
Profit margin-64.7%HEALTHCARE
Market cap$940.3MSmall cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 7.49
- P/S (TTM)
- 9.22
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -43.9%
- Operating margin
- -71.1%
- Revenue growth YoY
- 32.5%
- Dividend yield
- —
- Beta
- —
Last earnings
Aug 10, 2026 · Estimate $-0.45 · Reported $-0.51
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About CeriBell, Inc
Company profileCeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 360 NORTH PASTORIA AVENUE, SUNNYVALE, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$940.3M
Shares outstanding$38.4M
52W high$25.63
52W low$10.85
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent